BioCatalystWatch
SIONWorkspace / SION / OverviewCompany library
Sionna Therapeutics, Inc. logo

Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. (SION)

Website

Price
Market cap
Next catalystExpected Q1 2027SION-451 + galicaftor (SION-2222) — AscenSION CF · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

SION-451SION-451 + galicaftor (SION-2222) — AscenSION CF

CFTR (NBD1 and TMD1)

PreINDP1P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

SION-451SION-451 + galicaftor (SION-2222) — AscenSION CF

CFTR (NBD1 and TMD1)

PreINDP1P3FilingApproved
Upcoming / outlook

Other pipelines

SION-3067 (navocaftor)

CFTR

PreINDP1P2P3FilingApproved
SION-109

CFTR (ICL4–NBD1 interface)

PreINDP1P2P3FilingApproved
SION-2851

CFTR (TMD1)

PreINDP1P2P3FilingApproved

History / paused

CFTR (NBD1)

PreINDP1P2P3FilingApproved
SION-451

CFTR (NBD1 and TMD1)

PreINDP1P2P3FilingApproved
SION-451

CFTR (NBD1 and ICL4)

PreINDP1P2P3FilingApproved

CFTR (NBD1)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status
3M3M

Market Reaction / Supply Context

Market Structure

SION PR & News

PR & News

SION SEC archive